tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Arbutus Biopharma’s Long-Term Hepatitis B Study: A Potential Game-Changer for Investors
PremiumCompany AnnouncementsArbutus Biopharma’s Long-Term Hepatitis B Study: A Potential Game-Changer for Investors
2M ago
Arbutus Biopharma Showcases Data at Liver Meeting 2025
Premium
Company Announcements
Arbutus Biopharma Showcases Data at Liver Meeting 2025
3M ago
Arbutus Biopharma to present imdusiran, AB-101 data at The Liver Meeting 2025
Premium
The Fly
Arbutus Biopharma to present imdusiran, AB-101 data at The Liver Meeting 2025
3M ago
Arbutus Biopharma’s AB-101 Study: A Potential Game-Changer in Chronic Hepatitis B Treatment
PremiumCompany AnnouncementsArbutus Biopharma’s AB-101 Study: A Potential Game-Changer in Chronic Hepatitis B Treatment
5M ago
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical
Premium
Company Announcements
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical
6M ago
Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB
Premium
The Fly
Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB
6M ago
Arbutus Biopharma Unveils Promising HBV Treatment Data
PremiumCompany AnnouncementsArbutus Biopharma Unveils Promising HBV Treatment Data
8M ago
Arbutus Biopharma presents data from two HBV assets
Premium
The Fly
Arbutus Biopharma presents data from two HBV assets
8M ago
Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025
Premium
Company Announcements
Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100